Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mDC3/8-KRAS Vaccine in Resected Pancreatic Cancer
NCT03592888Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Nov 2018
- Primary completion
- Feb 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mDC3/8-KRAS vaccine in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Pennsylvania. Primary endpoint: Safety and side effects of vaccine per CTCAE 4.0. Started Nov 2018; status: completed.
02
Drugs
mDC3/8-KRAS vaccine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03592888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03592888.